Table 1.
Baseline characteristics and cardiac risk factors of patients with and without 6-week MACE
| Variablesa | Total population (n = 274) | 6-week MACE (n = 68) | No MACE at 6-weeks (n = 206) | P-value |
|---|---|---|---|---|
| Age, mean (SD) | 53.33 | 60.60 | 50.93 | > 0.001 |
| Male gender, n (%) | 170 (62.04%) | 58 (85.29%) | 112 (54.36%) | > 0.001 |
| Smoker, n (%) | 100 (36.49%) | 37 (54.41%) | 63 (30.58%) | 0.001 |
| Hypertension, n (%) | 126 (45.98%) | 36 (52.94%) | 90 (43.68%) | 0.184 |
| Hypercholesterolemia, n (%) | 93 (33.94%) | 34 (50%) | 59 (28.64%) | 0.001 |
| Diabetes, n (%) | 57 (20.8%) | 17 (25%) | 40 (19.41%) | 0.325 |
| Family history, n (%) | 65 (23.72%) | 16 (23.52%) | 49 (23.78%) | 0.846 |
| BMI < 30 | 61 (22.26%) | 18 (26.48) | 43 (20.87%) | 0.336 |
| ASA useb, n (%) | 95 (34.67%) | 34 (50%) | 61 (29.61%) | 0.002 |
| History of CAD (documented coronary stenosis), n (%) | 65 (23.72%) | 29 (42.64%) | 36 (17.47%) | > 0.001 |
a No missing data was observed for the variables listed. All data was complete and available for analysis
b Use of Aspirin Whitin one week before presentation